early
phase
clinical
trials
raised
enthusiasm
insulin
growth
factor
receptor
igf
specific
antibodies
cancer
treatment
initial
phase
iii
results
unselected
patients
disappointing
clinical
studies
benefit
predictive
biomarkers
identify
probable
responders
rational
combination
therapies
consideration
alternative
targeting
strategies
ligand
specific
antibodies
receptor
specific
tyrosine
kinase
inhibitors
targeting
insulin
igf
signalling
considered
broader
context
pathophysiology
relates
obesity
diabetes
neoplasia
effects
anti
diabetic
drugs
including
metformin
cancer
risk
prognosis
insulin
igfi
receptor
family
relevant
development
pi
akt
pathway
